ANSWER: C

Rationale:

This vignette requires identifying which medications most directly produced both the ulcer and the bleeding failure at the ulcer site. Ibuprofen, as a non-selective COX inhibitor, contributes through two independent mechanisms: COX-1 inhibition in the gastric mucosa reduces prostaglandin E2 and prostacyclin synthesis, eliminating the cytoprotective mucus layer and bicarbonate secretion that shield the epithelium from acid, directly predisposing to ulcer formation; and COX-1 inhibition in platelets eliminates thromboxane A2 production, impairing the platelet activation response at the ulcer site. Sertraline contributes through platelet SERT blockade: over weeks of treatment, platelet dense granule serotonin stores are progressively depleted because platelets cannot synthesize replacement serotonin. At the gastric ulcer bleeding site, the depleted platelets cannot release serotonin to activate adjacent platelets via 5-HT2A receptors, impairing the amplification loop that normally strengthens the platelet plug. The combination of ibuprofen's dual gastric and antiplatelet effects with sertraline's platelet serotonin depletion is the most direct cause of both ulcer formation and inadequate hemostasis. Warfarin, while clearly contributing to systemic coagulopathy, did not cause the ulcer and the INR is therapeutic — warfarin's role is a contributing factor, not the primary driver of this specific presentation. Option A:

• Option A: Option A incorrectly identifies warfarin and sertraline as the primary agents and fabricates a mechanism for sertraline — sertraline does not stimulate gastric acid secretion through 5-HT3 receptor activation on parietal cells. Sertraline is a SERT inhibitor; its GI contribution is platelet serotonin depletion and modest direct mucosal effects, not parietal cell acid stimulation. Cyproheptadine would not be the appropriate reversal agent for sertraline's platelet effect. Option B: Option B correctly identifies warfarin and ibuprofen but understates ibuprofen's mechanism by attributing it solely to COX-2 inhibition promoting mucosal healing. The primary gastric toxicity of NSAIDs is through COX-1 inhibition reducing cytoprotective prostaglandins — not COX-2. Option B also incorrectly dismisses sertraline's platelet serotonin depletion as having no effect on platelet function, which contradicts well-established pharmacology and clinical evidence. Option D:
• Option D: Option D incorrectly attributes the entire presentation to sertraline alone and fabricates an off-target COX-1 inhibitory mechanism for sertraline at doses above 75 mg. Sertraline is not a COX inhibitor at any therapeutic dose; its GI bleeding contribution operates exclusively through platelet SERT blockade, not through direct mucosal injury. This option dismisses the well-established gastrotoxicity of ibuprofen. Option E: Option E correctly identifies ibuprofen and warfarin but dismisses sertraline's platelet contribution as merely theoretical. Multiple observational studies and meta-analyses have demonstrated a clinically significant increase in GI bleeding risk with SSRI use, particularly in combination with NSAIDs and anticoagulants — this is not a theoretical concern but an established clinical risk that warrants consideration in management decisions.

ANSWER: A

Rationale:

This vignette is a classic presentation of serotonin syndrome precipitated by a drug combination that is frequently overlooked because neither agent is a traditional psychiatric medication. Linezolid is an oxazolidinone antibiotic used to treat resistant gram-positive infections; in addition to its antibacterial mechanism (inhibition of bacterial ribosomal protein synthesis), linezolid inhibits MAO-A as a pharmacologically significant off-target effect, reducing serotonin catabolism. Tramadol is a centrally acting analgesic with two mechanisms: mu-opioid receptor agonism and inhibition of serotonin and norepinephrine reuptake (SERT and NET blockade). The combination of linezolid's MAO-A inhibition with tramadol's SERT blockade creates the conditions for serotonin syndrome — serotonin can neither be degraded by MAO-A nor be reuptaken by SERT, causing CNS accumulation that overstimulates 5-HT2A receptors (producing clonus and tremor) and contributes to autonomic instability (diaphoresis, tachycardia, hyperthermia). The absence of rigidity distinguishes this from neuroleptic malignant syndrome, which characteristically produces lead-pipe rigidity. Immediate management requires stopping both offending agents, using benzodiazepines to control neuromuscular hyperactivity and assist with temperature reduction, and considering cyproheptadine (a non-selective 5-HT2A and 5-HT1 antagonist) for moderate-to-severe cases. Alternative IV analgesia not involving serotonergic mechanisms should be substituted for tramadol. Option B:

• Option B: Option B incorrectly diagnoses this as neuroleptic malignant syndrome and invents a D2 receptor blockade mechanism for linezolid. Linezolid does not block D2 receptors; NMS is caused by dopamine receptor antagonism from antipsychotics or antiemetics with D2 blockade. Furthermore, the presentation lacks the characteristic lead-pipe rigidity and bradykinesia of NMS, and clonus is a finding of serotonin syndrome rather than NMS. Option C:
• Option C: Option C incorrectly diagnoses anticholinergic toxidrome and fabricates muscarinic receptor blockade as a linezolid mechanism. Anticholinergic toxidrome characteristically produces dry, flushed skin and absent bowel sounds — the opposite of the diaphoresis seen here. Neither linezolid nor tramadol is a muscarinic antagonist, and physostigmine would be inappropriate treatment for serotonin syndrome. Option D:
• Option D: Option D incorrectly attributes the presentation to opioid toxicity via CYP3A4 inhibition by linezolid raising tramadol levels. Linezolid does not significantly inhibit CYP3A4. More importantly, opioid toxicity presents with miosis, respiratory depression, and sedation — not with the agitation, clonus, and hyperthermia of serotonin syndrome. Naloxone would not be the appropriate treatment for this presentation. Option E: Option E invents a blood-brain barrier destabilization mechanism for linezolid that has no pharmacological basis. Linezolid does cross the blood-brain barrier adequately for CNS infections, but the mechanism of this presentation is MAO-A inhibition combined with tramadol's SERT blockade — not CNS drug accumulation from barrier disruption. Continuing linezolid while stopping tramadol would leave the MAO-A inhibition in place, which remains dangerous if any serotonergic agent is given subsequently.

ANSWER: E

Rationale:

Telotristat ethyl's mechanism is inhibition of TPH1, the rate-limiting enzyme for serotonin synthesis in peripheral enterochromaffin cells. The pharmacodynamic biomarker that most directly confirms this mechanism is 24-hour urinary 5-HIAA. The biochemical logic is straightforward and follows the serotonin catabolic pathway: TPH1 inhibition reduces serotonin synthesis in EC cells → less serotonin is produced and enters the portal circulation → less serotonin is available for MAO-A-mediated oxidative deamination to the aldehyde intermediate → less 5-HIAA is produced by ALDH2 → less 5-HIAA appears in the urine. A reduction in 24-hour urinary 5-HIAA therefore directly reflects reduced EC cell serotonin production, confirming that telotristat is achieving its intended pharmacodynamic effect at the biosynthetic level. In the pivotal clinical trials for telotristat (TELESTAR and TELECAST), reduction in urinary 5-HIAA was the primary pharmacodynamic endpoint used to confirm mechanism engagement, and meaningful reductions in 5-HIAA correlated with improvements in bowel frequency. This biomarker specifically reflects serotonin synthesis inhibition, distinguishing telotristat's mechanism from the secretion-suppressing mechanism of somatostatin analogs. Option A:

• Option A: Option A is incorrect because chromogranin A is a marker of overall neuroendocrine tumor secretory activity and bulk, not a specific pharmacodynamic marker of TPH1 inhibition. While chromogranin A may decrease if the tumor burden decreases, it is not selectively responsive to changes in serotonin synthesis and would not specifically confirm the mechanism of telotristat. It is more useful as a tumor burden marker than a pharmacodynamic biomarker for this drug. Option B:
• Option B: Option B is incorrect because platelet-poor plasma serotonin is not the established pharmacodynamic biomarker for telotristat, and free plasma serotonin is not reliably reduced within 48 hours of starting treatment as suggested. Urinary 5-HIAA, which reflects the catabolism of all serotonin produced by EC cells, is the established and validated pharmacodynamic endpoint in telotristat clinical trials. Plasma serotonin measurement is technically challenging and subject to preanalytical variability from platelet contamination. Option C: Option C invents a mechanism — telotristat reducing CGRP through reduced EC cell serotonin co-release stimulation of enteric neurons — that has no established basis in telotristat pharmacology. CGRP is released from trigeminal nerve terminals and is relevant to migraine pathophysiology, not to carcinoid syndrome or to the pharmacodynamic monitoring of TPH1 inhibitors. Plasma CGRP is not a validated biomarker for carcinoid syndrome treatment response. Option D: Option D proposes fecal serotonin as a more direct biomarker than urinary 5-HIAA. While measuring stool serotonin content is technically feasible in research settings, it is not the established clinical biomarker for telotristat response. Urinary 5-HIAA is not merely indirect — it is mechanistically directly linked to the rate of serotonin production through the MAO-A/ALDH2 catabolic pathway, and the reduction of dietary confounders through dietary restriction before collection is a routine and manageable preanalytical step.

ANSWER: B

Rationale:

The contraindication for sumatriptan and all triptans in hemiplegic migraine is vascular — not genetic, not based on receptor expression differences, and not related to a lack of therapeutic efficacy. Sumatriptan acts as a 5-HT1B/1D receptor agonist. At 5-HT1B receptors on cranial vascular smooth muscle, including the basilar artery and the penetrating cortical arterioles that supply deep and cortical brain structures, sumatriptan produces vasoconstriction. In uncomplicated migraine with typical aura, this vasoconstriction is generally well tolerated because cerebral autoregulation maintains adequate parenchymal perfusion. In hemiplegic migraine and basilar-type migraine, the pathophysiology involves cortical spreading depression — a propagating wave of neuronal and glial depolarization — that is accompanied by a phase of oligemia (relative reduction in cerebral blood flow) in the affected territory, which in this patient includes the motor cortex. Adding sumatriptan-induced 5-HT1B-mediated arterial vasoconstriction to a territory already experiencing reduced perfusion creates a mechanistically plausible and clinically recognized risk of ischemic infarction or stroke. Current headache society guidelines contraindicate all triptans in hemiplegic and basilar-type migraine on this basis. A pharmacologically appropriate acute alternative is an NSAID such as ibuprofen or naproxen combined with an antiemetic such as metoclopramide (for nausea and to improve NSAID absorption) — neither carries vasoconstrictor risk in the cerebral circulation. Option A:

• Option A: Option A incorrectly attributes hemiplegic migraine to excess serotonin release at the trigeminal ganglion and proposes cyproheptadine as the alternative. Hemiplegic migraine is caused by ion channel dysfunction — most commonly mutations in CACNA1A (P/Q-type calcium channel), ATP1A2 (Na/K-ATPase), or SCN1A (sodium channel) — leading to cortical spreading depression and oligemia. Cyproheptadine is occasionally used in migraine prevention but has no role as an acute therapy, and the proposed mechanism for the contraindication is incorrect. Option C:
• Option C: Option C inverts the direction of the pharmacogenomic concern: mutations in CACNA1A in familial hemiplegic migraine do not cause sumatriptan to bind 5-HT1B receptors in cardiac tissue with higher affinity. The contraindication does not require genetic testing to implement and applies to all forms of hemiplegic migraine, sporadic and familial alike, based on the vascular perfusion risk rather than a receptor pharmacology change. Option D:
• Option D: Option D incorrectly claims that sumatriptan is contraindicated because it would be ineffective rather than unsafe, and that hemiplegic migraine headache is not driven by vascular mechanisms. The headache phase of hemiplegic migraine does involve trigeminovascular activation and cranial vascular components similar to typical migraine, and triptans can be effective — the contraindication is specifically a safety concern about ischemia, not a therapeutic futility argument. Valproate is used for migraine prevention, not acute treatment. Option E:
• Option E: Option E fabricates a mechanism involving oligodendrocyte 5-HT1B receptors and transient demyelination that has no established basis in migraine pathophysiology or serotonin pharmacology. The motor weakness in hemiplegic migraine reflects transient neuronal dysfunction from cortical spreading depression and oligemia, not demyelination — recovery occurs spontaneously within hours and is not dependent on myelin repair.

ANSWER: D

Rationale:

This vignette requires applying knowledge of intraclass differences among 5-HT3 antagonists to a patient with a specific cardiac risk factor. Palonosetron is the preferred agent for two pharmacologically distinct reasons that address both the safety concern and the clinical need. First, regarding cardiac safety: all 5-HT3 antagonists carry some degree of QT-prolonging potential, but the magnitude differs substantially by agent. Ondansetron has the highest hERG potassium channel affinity in this class — its off-target blockade of the IKr current (the rapidly activating delayed rectifier potassium current responsible for ventricular repolarization) is more potent than that of granisetron or palonosetron. Palonosetron has substantially lower hERG channel affinity and produces significantly less QT prolongation in pharmacological and clinical studies. In a patient whose baseline QTc is already 462 milliseconds — borderline prolonged — minimizing additional QTc prolongation is an important safety consideration that favors palonosetron over ondansetron. Second, regarding clinical efficacy: palonosetron's plasma half-life of approximately 40 hours and its cooperative allosteric binding with receptor internalization provide superior coverage of delayed-phase CINV from cisplatin, which peaks 48 to 72 hours after chemotherapy administration. A single pre-chemotherapy dose of palonosetron provides continuous coverage through both acute and delayed phases, whereas ondansetron's 3 to 5 hour half-life requires repeated dosing. Option A:

• Option A: Option A incorrectly minimizes ondansetron's QT risk at standard doses in patients with elevated baseline QTc. The FDA has issued safety communications regarding QTc prolongation with standard ondansetron doses and has specifically recommended avoiding ondansetron in patients with congenital long QT syndrome or those taking other QT-prolonging agents. In a patient with a baseline QTc of 462 ms, the additional QT prolongation from ondansetron is clinically relevant. The 32 mg single-dose restriction applies to a specifically withdrawn regimen but does not make all other doses safe for high-risk patients. Option B:
• Option B: Option B incorrectly attributes ondansetron's QT effect to 5-HT3 receptor blockade at the sinoatrial node rather than hERG channel blockade. QT prolongation from ondansetron is an off-target effect mediated by hERG/IKr blockade and is mechanistically unrelated to 5-HT3 receptor expression in cardiac tissue. Granisetron has lower hERG affinity than ondansetron but is not completely free of QT effect, and the mechanistic explanation provided is pharmacologically incorrect. Option C:
• Option C: Option C incorrectly asserts that all 5-HT3 antagonists produce equivalent QT prolongation through a shared 5-HT3 receptor mechanism. As established above, QT prolongation from this class is caused by off-target hERG channel blockade — a drug-specific property that varies substantially among class members — not by 5-HT3 receptor blockade itself. Palonosetron has meaningfully lower hERG affinity than ondansetron, making intraclass differences clinically important. Option E:
• Option E: Option E incorrectly states that the entire 5-HT3 antagonist class is contraindicated when baseline QTc exceeds 450 milliseconds. No such absolute QTc threshold contraindication applies to the entire class; palonosetron can be used with appropriate monitoring. Substituting metoclopramide, which has D2 antagonist activity and its own cardiac and neurological risks (including tardive dyskinesia with prolonged use), is not the recommended approach in this context.

ANSWER: C

Rationale:

The washout period before starting an irreversible MAOI is determined by how long SERT blockade persists after the SSRI is discontinued — not by the plasma half-life of the parent compound alone. For this patient on fluoxetine, the critical pharmacokinetic factor is norfluoxetine, an active metabolite formed by N-demethylation of fluoxetine. Norfluoxetine is itself a potent SERT inhibitor with a half-life of approximately 1 to 2 weeks — substantially longer than the parent compound's half-life of 1 to 4 days. After discontinuing fluoxetine, norfluoxetine plasma concentrations decline slowly over several weeks, maintaining SERT occupancy well beyond the time frame when plasma fluoxetine has become undetectable. To allow five half-lives of norfluoxetine to elapse — ensuring SERT occupancy has fallen to negligible levels — requires approximately 5 weeks. If phenelzine is started while significant SERT occupancy persists from residual norfluoxetine, the combination of SERT blockade (preventing serotonin reuptake) and irreversible MAO-A inhibition (preventing serotonin degradation) causes serotonin to accumulate to toxic levels, producing serotonin syndrome. Her colleague's antidepressant — paroxetine, sertraline, escitalopram, or citalopram — lacks a long-lived active metabolite with meaningful SERT affinity, so these drugs clear sufficiently within 14 days to make the standard 2-week washout safe before starting an MAOI. Option A:

• Option A: Option A understates the required washout at 4 weeks and incorrectly bases the calculation on the parent compound half-life of 7 days alone. The 5-week requirement is driven by norfluoxetine's half-life of 1 to 2 weeks, which is substantially longer than the parent compound. Using the parent compound half-life to calculate washout while ignoring the active metabolite is the specific pharmacokinetic error that leads to dangerous undercalculation of the required washout. Option B:
• Option B: Option B is incorrect and potentially dangerous — it dismisses the extended fluoxetine washout requirement as a misconception and advocates a uniform 14-day washout for all SSRIs. Current prescribing information for phenelzine and for fluoxetine explicitly states a minimum 5-week washout after fluoxetine before starting an irreversible MAOI, reflecting the established pharmacokinetics of norfluoxetine. Applying only 14 days after fluoxetine creates a genuine risk of serotonin syndrome. Option D: Option D invents a mechanism — irreversible CNS tissue depot formation by fluoxetine — that has no pharmacokinetic basis. Fluoxetine distributes extensively into tissues due to its lipophilicity, but it does not form an irreversible depot; it equilibrates between plasma and tissue compartments and is eliminated according to normal first-order kinetics governed by its and norfluoxetine's half-lives. The extended washout is entirely explained by norfluoxetine's pharmacokinetics, not by tissue sequestration. Option E:
• Option E: Option E incorrectly standardizes the 5-week washout for all SSRIs and retroactively classifies the shorter washout for her colleague as a prescribing error. SSRIs without long-lived active metabolites — paroxetine, sertraline, citalopram, escitalopram — are safely managed with a 14-day washout before an irreversible MAOI, and this is the current standard of care. Only fluoxetine requires the extended 5-week washout because of norfluoxetine.

ANSWER: A

Rationale:

Tardive dyskinesia is a well-recognized serious adverse effect of prolonged metoclopramide use and represents its most significant long-term risk. The mechanism arises from metoclopramide's D2 receptor antagonism: chronic D2 blockade in the basal ganglia — specifically in the nigrostriatal dopaminergic pathway — triggers a compensatory upregulation and supersensitization of postsynaptic D2 receptors. When these supersensitized receptors are periodically exposed to endogenous dopamine (during brief periods of reduced drug levels, or after discontinuation), their exaggerated response to dopaminergic input produces the involuntary hyperkinetic movements characteristic of tardive dyskinesia. The orofacial region is preferentially affected, producing the lip smacking, chewing, and tongue protrusion this patient demonstrates. Tardive dyskinesia can be irreversible even after the offending drug is stopped, which is why the FDA has mandated a black-box warning for metoclopramide restricting its use to 12 weeks or less in most clinical situations. Prucalopride is the pharmacologically appropriate replacement: as a highly selective 5-HT4 agonist without D2 antagonist activity, it produces prokinesis through Gs/cAMP stimulation of enteric neurons driving the ascending excitatory limb of the peristaltic reflex — the same therapeutic target as metoclopramide's 5-HT4 component — without any dopamine receptor interaction and therefore without the mechanism underlying tardive dyskinesia. Option B:

• Option B: Option B misidentifies this as an acute dystonic reaction rather than tardive dyskinesia. Acute dystonic reactions occur within hours to days of starting D2 antagonists and involve sustained abnormal posturing or muscle spasm — they are fully reversible with anticholinergics. Tardive dyskinesia develops after months of exposure, presents with repetitive choreiform movements (not sustained posturing), and may be irreversible. This patient's 6-month exposure and 2-month duration of symptoms clearly indicates tardive dyskinesia, not an acute reaction. Domperidone, with peripheral D2 restriction, is not an appropriate alternative when tardive dyskinesia has already developed. Option C: Option C invents a mechanism — 5-HT4 receptor overstimulation in the basal ganglia producing choreiform movements — that has no pharmacological basis. 5-HT4 receptors are expressed in the GI tract and to some extent in the brain, but their stimulation is not an established cause of tardive dyskinesia or choreiform movements. Metoclopramide's motor toxicity is entirely attributable to its D2 antagonism, not its 5-HT4 agonism, and ondansetron has no role in treating or preventing tardive dyskinesia. Option D: Option D invents a reactive oxygen species metabolite toxicity mechanism and incorrectly concludes that no pharmacological alternative is viable. Metoclopramide's motor toxicity is receptor-mediated D2 blockade, not metabolite-driven oxidative striatal damage, and prucalopride's lack of D2 activity makes it a viable alternative that specifically avoids the mechanism of harm. Option E: Option E invents a 5-HT4-mediated motor cortex mechanism for tardive dyskinesia and recommends domperidone on incorrect grounds. Tardive dyskinesia from metoclopramide is caused by D2 receptor supersensitization in the basal ganglia from chronic D2 blockade — not by cortical 5-HT4 stimulation. Domperidone has peripheral D2 restriction but still produces D2 blockade and carries its own cardiac safety concerns (QT prolongation); it is not available in the United States and does not address the mechanism of tardive dyskinesia.

ANSWER: E

Rationale:

This clinical scenario requires translating buspirone's autoreceptor pharmacology into patient counseling. Buspirone's delayed onset is not a failure of the drug or a dosing problem — it is a predictable consequence of its receptor-level mechanism. As a 5-HT1A partial agonist, buspirone acts simultaneously at two anatomical populations of 5-HT1A receptors. At the somatodendritic autoreceptors on raphe neurons, acute partial agonism reduces raphe neuron firing, transiently decreasing serotonin output to limbic targets — an effect that counteracts the intended postsynaptic anxiolytic effect. This acute autoreceptor-mediated suppression of serotonergic tone resolves over 2 to 4 weeks as the autoreceptors desensitize under sustained buspirone exposure. As desensitization progresses, postsynaptic limbic 5-HT1A receptor activation by both endogenous serotonin and buspirone itself increases, producing the Gi/Go-mediated inhibitory modulation of limbic circuitry that constitutes the anxiolytic effect. The contrast with lorazepam is mechanistically important: lorazepam potentiates GABA-A receptor chloride channel opening immediately upon binding, producing anxiolysis within minutes — a pharmacologically instantaneous mechanism that does not require autoreceptor desensitization. The patient should be counseled to continue buspirone and avoid restarting the benzodiazepine, as benzodiazepine dependence would undermine the goal of transitioning her to a non-addictive anxiolytic. Option A:

• Option A: Option A incorrectly states that buspirone is ineffective for GAD and should be stopped. Buspirone is an FDA-approved first-line treatment for generalized anxiety disorder with demonstrated efficacy in controlled trials. The appropriate response to a one-week call reporting no effect is to counsel the patient about the expected delay, not to discontinue the drug before the therapeutic window has been reached. Option B:
• Option B: Option B incorrectly attributes the lack of one-week response to sub-therapeutic dosing and recommends immediate dose escalation. The delay in buspirone response is pharmacodynamic — driven by autoreceptor desensitization kinetics — not pharmacokinetic. Buspirone reaches steady-state plasma levels within days of starting therapy; doubling the dose at one week does not accelerate autoreceptor desensitization and may increase adverse effects such as dizziness and nausea without therapeutic benefit. Option C: Option C correctly notes the absence of acute effect but mischaracterizes it as a confirmation of mechanism engagement with "no acute effect whatsoever." Buspirone does produce some detectable effects in the acute period — including sedation, dizziness, and mild anxiolysis in some patients — but the full anxiolytic effect emerges only with sustained treatment. Telling a patient that complete absence of any effect is a good sign is inaccurate and may undermine adherence. Option D: Option D correctly identifies the mechanistic independence of buspirone and lorazepam at different receptors, but the clinical recommendation to combine both at full doses indefinitely is not appropriate for a patient being transitioned away from benzodiazepine use. Concurrent full-dose benzodiazepine administration would reinforce benzodiazepine dependence and undermine the therapeutic rationale for the transition to buspirone. Short-term bridging benzodiazepine use during buspirone titration may be considered in select cases, but this requires careful clinical judgment and a defined taper plan — not unlimited combination therapy.

ANSWER: B

Rationale:

The tyramine reaction with irreversible MAO inhibitors is a pharmacological interaction mediated specifically by MAO-A. Tyramine is a biogenic amine present in fermented, aged, and cured foods including aged cheeses, cured meats, fermented beverages (particularly red wines), and soy-based products. Normally, tyramine absorbed from the GI tract encounters MAO-A expressed in intestinal enterocytes and hepatocytes during first-pass transit. MAO-A preferentially oxidizes tyramine at the concentrations encountered in the gut wall, converting it to 4-hydroxyphenylacetic acid before it can reach the systemic circulation. This gut wall first-pass catabolism provides an effective barrier that prevents dietary tyramine from reaching peripheral sympathetic nerve terminals. When MAO-A is irreversibly inhibited by phenelzine, this barrier is eliminated. Tyramine now passes into the portal circulation and systemic blood in pharmacologically active quantities. At peripheral sympathetic nerve terminals, tyramine acts as an indirect sympathomimetic — it enters the nerve terminal via the norepinephrine transporter and is taken into storage vesicles via VMAT, where it displaces norepinephrine through a carrier-mediated exchange mechanism (via the vesicular monoamine transporter acting in reverse). The displaced norepinephrine floods the synapse, producing an acute massive catecholamine surge and the severe hypertension, headache, and sympathomimetic features seen in this patient. This specific mechanism explains why selective MAO-B inhibitors at low therapeutic doses do not carry significant tyramine reaction risk — MAO-A in the gut wall remains active and continues to provide first-pass tyramine protection. Option A:

• Option A: Option A inverts the isoform: it incorrectly identifies MAO-B as the gut wall tyramine barrier and claims that selegiline carries high tyramine reaction risk. MAO-A is the dominant isoform in intestinal enterocytes for tyramine catabolism, not MAO-B. Selective MAO-B inhibitors such as selegiline at standard antiparkinsonian doses do not significantly inhibit intestinal MAO-A, preserving the tyramine barrier and producing substantially lower dietary interaction risk than non-selective or MAO-A-preferential inhibitors. Option C:
• Option C: Option C incorrectly attributes the mechanism to central MAO-A inhibition acting on hypothalamic sympathetic outflow, and incorrectly states that tyramine is not absorbed from the GI tract. Tyramine is readily absorbed from the gastrointestinal tract; the normal protective mechanism is its catabolism during absorption by MAO-A in enterocytes and hepatocytes. The catecholamine surge is peripheral — tyramine reaches peripheral sympathetic nerve terminals and displaces norepinephrine — not centrally mediated through hypothalamic stimulation. Option D:
• Option D: Option D incorrectly states that both MAO-A and MAO-B contribute equally to gut wall tyramine catabolism and incorrectly claims that selective MAO-B inhibitors are safe at any dose with dietary tyramine. MAO-A is the primary isoform responsible for intestinal tyramine catabolism. While very high doses of selegiline lose MAO-B selectivity and begin to inhibit MAO-A, standard therapeutic doses preserve MAO-A activity and the tyramine barrier — making selective MAO-B inhibitors substantially safer than non-selective MAOIs for dietary interactions at approved doses. Option E: Option E invents pharmacological mechanisms for both phenelzine (dopamine beta-hydroxylase inhibition) and the dietary components (synergistic pressor amines in cheese not metabolized by MAO) that have no basis in established pharmacology. Phenelzine's primary mechanism is MAO-A and MAO-B inhibition, not dopamine beta-hydroxylase inhibition, and the tyramine content of aged cheese and red wine is the well-established cause of this reaction.

ANSWER: D

Rationale:

This vignette requires identifying which co-medication adds a mechanistically distinct and independent second platelet-level bleeding risk. Escitalopram's bleeding risk operates through SERT blockade on platelets: by preventing serotonin reuptake, escitalopram progressively depletes platelet dense granule serotonin stores. At the surgical site, platelets with depleted serotonin cannot release serotonin to activate adjacent platelets via 5-HT2A receptors, impairing the serotonin-mediated amplification loop. Ibuprofen adds a completely different and independent mechanism: as a non-selective COX inhibitor, ibuprofen irreversibly inhibits COX-1 in platelets. Platelet COX-1 converts arachidonic acid to thromboxane A2, a potent platelet activator that amplifies aggregation through Gq-coupled TP receptors on platelet membranes. This thromboxane A2-dependent amplification pathway is entirely separate from the serotonin/5-HT2A amplification pathway — they operate through different lipid-derived versus amine mediators, different surface receptors, and different intracellular signaling cascades. When both are simultaneously impaired — SERT blockade depleting serotonin and COX-1 inhibition eliminating thromboxane A2 — two independent amplification loops of platelet activation are removed, producing additive impairment of platelet plug formation. This combination is well recognized as a clinically significant predictor of increased perioperative bleeding risk, and the ibuprofen should be discontinued at least 5 days before elective surgery. Option A:

• Option A: Option A incorrectly dismisses ibuprofen's platelet effect by attributing its analgesia to COX-2 inhibition alone. Ibuprofen is a non-selective COX inhibitor with significant COX-1 activity at standard doses, and COX-1 inhibition in platelets at 400 mg twice daily produces clinically meaningful reduction in thromboxane A2 synthesis. The distinction between COX-1 and COX-2 inhibition is relevant for selective COX-2 inhibitors (celecoxib), not for ibuprofen, which inhibits both isoforms. Option B: Option B invents a beta-adrenergic mechanism for platelet proaggregability through metoprolol's beta-2 blockade. While platelet beta-2 receptors do exist, their blockade by therapeutic doses of cardioselective beta-blockers such as metoprolol does not produce clinically significant platelet activation or bleeding risk modification. This mechanism is not established as a perioperative bleeding risk factor and does not represent an independent platelet-level risk additive with SSRI use. Option C: Option C invents a mechanism for omeprazole — inhibition of platelet vacuolar ATPase preventing dense granule serotonin secretion — that has no established pharmacological basis. Omeprazole's proton pump inhibition is specific to the gastric H⁺/K⁺-ATPase and does not meaningfully affect platelet function. Omeprazole is actually often co-prescribed with NSAIDs and SSRIs specifically to reduce GI bleeding risk, not as an additional platelet inhibitor. Option E: Option E invents a mechanism for vitamin D — thrombopoietin receptor signaling inhibition in megakaryocytes reducing platelet production — that has no established pharmacological basis at standard supplementation doses. Vitamin D at 2000 IU daily is not associated with clinically significant thrombocytopenia or platelet function impairment and is not a recognized perioperative bleeding risk factor.

ANSWER: C

Rationale:

This is a classic presentation of serotonin syndrome precipitated by combining a prescription SERT inhibitor with an over-the-counter herbal supplement that has SERT-inhibiting activity — a drug interaction that patients frequently do not recognize as dangerous because herbal supplements are not perceived as medications. St. John's Wort (Hypericum perforatum) contains hyperforin as its primary pharmacologically active constituent. Hyperforin inhibits the reuptake of serotonin, norepinephrine, and dopamine through a mechanism that includes SERT and NET inhibition, producing pharmacological effects functionally similar to an SNRI. When hyperforin's SERT-inhibiting activity is combined with sertraline's SERT blockade, the combined degree of SERT inhibition exceeds what either agent produces alone, causing greater accumulation of synaptic serotonin than sertraline alone would produce at the therapeutic dose. Excess CNS serotonin overstimulates 5-HT2A receptors on cortical and spinal neurons, producing the characteristic neuromuscular triad: clonus, hyperreflexia, and tremor. The autonomic features — hyperthermia, diaphoresis, tachycardia, and mydriasis — reflect combined 5-HT1A and 5-HT2A overstimulation affecting autonomic regulatory centers. The absence of rigidity distinguishes serotonin syndrome from neuroleptic malignant syndrome. First-line management requires stopping both SERT-inhibiting agents. Benzodiazepines are the cornerstone of acute management, reducing neuromuscular hyperactivity, controlling agitation, and facilitating thermoregulation. Cyproheptadine, a non-selective 5-HT2A and 5-HT1 antagonist, is used for moderate-to-severe cases to directly reduce serotonergic receptor overstimulation. Option A: Option A invents a tyramine-mediated sympathomimetic mechanism for St. John's Wort that has no pharmacological basis. St. John's Wort does not contain significant tyramine, and sertraline is not a MAO-A inhibitor. The presentation of clonus and hyperreflexia is characteristic of serotonin syndrome, not of tyramine-induced catecholamine release, which would produce hypertensive crisis without the neuromuscular features. Phentolamine and naloxone are not appropriate treatments for serotonin syndrome. Option B: Option B invents an allergic cross-reactivity mechanism between hyperforin and sertraline's chemical structure. There is no established allergic cross-reactivity between St. John's Wort components and sertraline, and the clinical presentation — with clonus, hyperreflexia, and autonomic instability rather than urticaria, angioedema, or bronchospasm — is not consistent with anaphylaxis. Epinephrine and diphenhydramine are not indicated for serotonin syndrome. Option D:

• Option D: Option D incorrectly identifies the mechanism as pharmacokinetic — St. John's Wort raising sertraline levels by inhibiting its metabolism. In fact, St. John's Wort is a potent inducer of CYP3A4 and P-glycoprotein, which typically reduces plasma levels of co-administered drugs rather than raising them. The serotonin syndrome mechanism is pharmacodynamic — additive SERT inhibition — not pharmacokinetic accumulation of sertraline. Activated charcoal would not be the appropriate management for an interaction that is already pharmacodynamically active. Option E:
• Option E: Option E inverts St. John's Wort's effect on CYP3A4 — it is an inducer, not an inhibitor — and invents a neurotoxic sertraline metabolite formed by CYP3A4 induction that directly stimulates 5-HT2A receptors. No such metabolite exists, and the mechanism of this interaction is pharmacodynamic SERT inhibition. Flumazenil reverses benzodiazepine effects and has no role in managing serotonin syndrome.